Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.450
-0.030 (-2.03%)
At close: Oct 8, 2026, 4:00 PM EDT
1.520
+0.070 (4.83%)
After-hours: Oct 8, 2026, 7:30 PM EDT
Palisade Bio Employees
Palisade Bio had 14 employees as of December 31, 2025. The number of employees increased by 6 or 75.00% compared to the previous year. That makes Palisade Bio the 39,313th largest employer in the world and 5,826th in the United States.
Employees
14
Change (1Y)
6
Growth (1Y)
75.00%
Revenue / Employee
$35,714
Profits / Employee
-$2,281,500
Market Cap
252.69M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | 6 | 75.00% |
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Fate Therapeutics | 161 |
| Sutro Biopharma | 128 |
| Nautilus Biotechnology | 127 |
| AC Immune | 122 |
| Zentalis Pharmaceuticals | 106 |
| SAB Biotherapeutics | 86 |
| Upstream Bio | 75 |
PALI News
- 7 hours ago - Palisade Bio initiated with an Outperform at Raymond James - TheFly
- 10 days ago - Palisade Bio to present clinical, translational data for PALI-2108 at UEG Week - TheFly
- 10 days ago - Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026 - GlobeNewsWire
- 15 days ago - Palisade Bio Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts
- 15 days ago - Palisade Bio expands Phase 2b Ascentra-UC with Health Canada CTA clearance - TheFly
- 15 days ago - Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance - GlobeNewsWire
- 16 days ago - Palisade Bio receives FDA clearance of IND for PALI-2108 - TheFly
- 16 days ago - Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD - GlobeNewsWire